Trial Search Results

18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas

To evaluate 18F-FDOPA PET obtained from PET/CT or PET/MRI imaging in patients with newly diagnosed or recurrent gliomas.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Erik Mittra

Collaborator: National Cancer Institute (NCI)


  • Drug: 18F-fluoro-dihydroxyphenylalanine
  • Procedure: Positron emission tomography (PET)
  • Procedure: Computed tomography (CT)
  • Procedure: Magnetic resonance imaging




Inclusion Criteria:

   - Greater than 15 year-old at the time of radiotracer administration

   - Provides written informed consent

   - Suspected new diagnosis or suspected recurrence of glioma

   - Able to remain still for duration of each imaging procedure (about 20 minutes)

Exclusion Criteria:

   - Less than 15 year-old at the time of radiotracer administra

   - Unable to provide informed consent

   - Inability to lie still for the entire imaging time

   - Inability to complete the needed investigational and standard-of-care imaging
   examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)

   - Any additional medical condition, serious intercurrent illness, or other extenuating
   circumstance that, in the opinion of the Investigator, may significantly interfere
   with study compliance

Ages Eligible for Study

16 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Andrei Iagaru
Not Recruiting